A nemia has been identified as a prognostic marker in multiple heart failure (HF) studies but has not consistently been used in clinical decision making. This may be related to the fact that we do not completely understand its implication in HF. The prevalence of anemia in HF with reduced ejection fraction (HFrEF) varies from 4% to 61%. 1, 2 It increases with the severity of HF symptoms, age, and the presence of chronic kidney disease (CKD). 1, 2 The prevalence of moderate CKD varies from 21% to 50% in HF. 3 CKD and anemia are independent prognostic markers with respect to mortality and hospitalizations in HF.
diabetes mellitus, and elevated systolic blood pressure were independent predictors of lower hemoglobin. 4 
Study Objectives
By comparing the clinical, echocardiographic, and biomarkers profiles of patients with HF with and without anemia with those of patients with CKD without systolic dysfunction, we aimed to improve our understanding of the mechanisms involved in the relationship between anemia and HF severity. More specifically, we wished to clarify the importance of CKD, left ventricular (LV) remodeling, and inflammation further in patients with anemia and HFrEF in comparison with those without anemia.
Methods

Study Design
We conducted the ANemia in CHhronic heart failure: Etiology, comparisons with renal disease, and relationships with biOmarkers and LV Remodeling (ANCHOR) study in 7 Canadian centers from 2008 to 2010; where the study had been approved by institutional review committees. The subjects gave informed consent. Measurements of stored biomarkers samples were subsequently completed, and statistical analyses were finalized in September 2013. As shown in Figure 1 , using a cross-sectional study design, we compared 3 groups of patients. One had HFrEF and anemia, defined as hemoglobin <120g/L in women and <130g/L in men (World Health Organization 2011), a second had HFrEF without anemia, and the third had CKD (estimating glomerular filtration rate [eGFR], <60 mL/min per 1.73 m 2 ) with preserved EF (≥50%) and were not identified based on HF symptoms.
Patient Population: Inclusion and Exclusion Criteria
Patients in groups 1 and 2 had an HF diagnosis ≥6 months before enrollment, were in New York Heart Association functional class II to IV, and received recommended HF therapy at stable doses for ≥1 month at the time of enrollment. Other inclusion criteria were age >18 years and LVEF≤40% within 6 months.
In group 3, patients recruited from outpatient clinics or echocardiography laboratories had CKD with or without anemia, and a LVEF≥50% documented within 6 months.
In all groups, patients were excluded if they had a recent acute renal failure episode (<1 month); red blood cells, other blood component transfusions, or erythropoietin therapy within 3 months; iron, B12, or folic acid supplements used to treat anemia (<3 months); evidence of active gastrointestinal bleeding; recent acute coronary syndrome or decompensated HF episode (<1 month); complex congenital heart disease; known malignant hematologic or other active neoplasia; immunosuppressive therapy, chemotherapy, or radiotherapy within 3 months; recent acute decompensation of a chronic inflammatory disease within 3 months; recent viral or bacterial syndrome (<2 weeks); and active or recent viral hepatitis (<3 months).
Pregnant women and patients unable to provide informed consent were also excluded.
Data Collection
Two visits were performed within 2 weeks. During the first one, we collected demographics, medical history, current medications, New York Heart Association class, Canadian Cardiovascular Society angina class, cardiovascular physical examination, vital signs, weight, height, waist measurement, oxygen saturation, eGFR, electrolytes, urea, creatinine, complete blood count, and an ECG. During the second visit, the patient's clinical stability was reviewed and repeat vital signs, weight, oxygen saturation, biomarkers for local and central laboratory measurements, and echocardiography were obtained. Figure 2 summarizes the rationale for the choice of selected biomarkers through the pathophysiology of anemia in HF. The samples were stored at the Montreal Heart Institute at −80°C until central laboratory analyses were performed.
Renal Function
Renal function was evaluated by measuring serum creatinine in our central laboratory and by eGFR, using the CKD-Epidemiology Collaboration Group equation. 10 Cystatin C (Siemens Healthcare Diagnostics) and neutrophil gelatinase-associated lipocalin (R&D Systems) were measured as potential novel indicators of renal function.
Echocardiographic Data
Echocardiography was performed within 96 hours of blood sample collection, using a phased-array imaging system equipped with a transducer with second harmonics capability. Images were obtained in the parasternal long-and short-axis and apical views. All images were stored on CD-ROM and analyzed off-line (ProSolv). All participating sites received a detailed imaging manual and were certified by the core laboratory at the Montreal Heart Institute. Three sonographers blinded to study group (supervised by 2 cardiologists) performed the measurements according to the American Society of Echocardiography standards. Each parameter was analyzed on 3 consecutive cycles (5 if atrial fibrillation). Inter-reader and intrareader variability was excellent, as previously reported.
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Serum Biomarkers
The prognostic serum markers troponin T and NT-proBNP were measured by electrochemiluminescent immunoassays (Roche Diagnostics). Analyses of aldosterone, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6, IL-10, erythropoietin, transforming growth factor-β1, and hepcidin were performed using ELISA, according to manufacturer's instructions.
The following circulating markers of ventricular remodeling were measured: the matrix metalloproteinases (MMP-2 and MMP-9), tissue inhibitor of matrix metalloproteinase 1 (TIMP-1; R&D Systems), and procollagen type III N-terminal peptide (Orion Diagnostics). The oxidative stress marker F2-isoprostane was measured according to manufacturer's instructions. 12 For selected novel biomarkers, samples from 30 healthy volunteers (25-72 years old, no known disease and taking no medications) were analyzed to obtain local references for normal values. Standard biochemical and hematologic analyses were performed at participating centers.
Sample Size Calculation
Sample size was based on TNF-α, which was the most described inflammatory biomarker (in terms of statistics) in HF and in CKD at the time our study was designed. On the basis of biochemical methodology and references available, 8, 13, 14 we had aimed at detecting a difference in TNF-α concentration of 10 pg/mL between any 2 groups and assumed a SD of 12 pg/mL. A sample size of 40 patients per group would then provide ≈90% power with a type I error rate of 0.0167 (to adjust for multiple comparisons). Considering a potential 20% rate of uncompleted tests, 50 patients per group were required for this study. 
Statistical Analysis
Patients who met inclusion and exclusion criteria were included in the analyses. Summary statistics are presented for all variables: n, mean±SD, or median (interquartile range) are displayed for continuous variables; frequency and percentage are provided for categorical variables.
Baseline characteristics and echocardiographic parameters were compared among the 3 groups using ANOVA models or χ 2 tests. Biomarkers were analyzed similarly. For continuous biomarkers, contrasts were performed using Tukey method to compare specific groups.
Because groups may not be readily comparable in absence of randomization, groups 1 and 2 were also compared on selected biomarkers (representing a given pathophysiological mechanism in systolic HF) using ANCOVA or logistic regression models, to control for cofactors that could influence outcomes. These cofactors or comorbid conditions would likely be related to cardiovascular events in patients with HFrEF and were selected on the basis of previous HF studies, as well as on differences observed in baseline characteristics of participants in this study. This adjusted analysis was performed to extract the biomarkers with most potential for explaining the different pathophysiological mechanisms exacerbated (and likely influencing prognosis) in patients with anemia and HFrEF, once clinical and paraclinical (other than anemia) factors known to have prognostic implications are taken into consideration. For the analysis of renal function-related biomarkers, eGFR was not included as a cofactor.
The relationship between hemoglobin and the cofactors defined above, with the addition of IL-10 and MMP-9/TIMP-1 ratio, was conducted using stepwise multiple linear regressions with hemoglobin as the dependent variable. A model was fit for groups 1 and 2 combined and 1 for group 3 only. The associations between hemoglobin and biomarkers were also analyzed using Pearson correlations.
Some variables were log-transformed before the analysis to respect the normality assumption better. These variables are presented as median (interquartile range) and the P values reported come from models based on log-transformed data. Statistical analysis was performed using SAS version 9.1, and the significance level was set to 0.05.
Results
Baseline Characteristics
The characteristics of the study population are presented in Table 1 . When compared with patients in group 2 (n=54), patients with anemia and HFrEF (group 1; n=48) were older, had more documented coronary artery disease, diabetes mellitus, hypertension, and atrial fibrillation or flutter on ECG. They also had been more frequently hospitalized for HF and for other causes within the previous year and had more signs of congestion and lower arterial blood pressure. In terms of HF therapy, patients in group 1 more often received mineralocorticoid receptor antagonists, digitalis, long-acting nitrates, oral anticoagulants, and amiodarone compared with patients in group 2. There was no difference in cardiac resynchronization therapy: 16.7% in group 1 and 13.0% in group 2. Patients in group 3 (CKD-preserved EF; n=49), when compared with patients in group 1, were slightly older, had less history of myocardial infarction, similar prevalence of atrial fibrillation/flutter, had been less frequently hospitalized for HF or other causes, had less signs of congestion, and had higher blood pressures. N/A: considering the study design, comparisons not indicated for these variables. ACEI indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; eGFR, estimating glomerular filtration rate; EPI, Epidemiology Collaboration Group; HF, heart failure; LVEF, left ventricular ejection fraction; N/A, not applicable; NT-proBNP, N-terminal probrain natriuretic peptide; and NYHA, New York Heart Association. *Groups 1, 2, and 3 compared unless otherwise specified. †LVEF reported in clinical setting within 6 mo of inclusion.
Commonly Used Circulating Biomarkers in HF
Patients in group 1 had higher NT-proBNP levels and more often elevated troponin T values when compared with patients in group 2 ( Table 2) . We assessed both New York Heart Association class and NT-proBNP in all patients, including group 3. Despite their renal dysfunction (which would be expected to raise NT-proBNP levels) and frequent anemia, only 18.4% of group 3 patients had both New York Heart Association ≥2 and elevated NT-proBNP; suggesting that HF with preserved EF was not a major contributor to our findings. A portrait of BUN indicates blood urea nitrogen; eGFR, estimating glomerular filtration rate; EPO, erythropoietin; hs-CRP, high-sensitivity-C-reactive protein; IL, interleukin; MMP, matrix metalloproteinase; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal probrain natriuretic peptide; PIIINP, procollagen type III N-terminal peptide; TIMP-1, tissue inhibitor of matrix metalloproteinase 1; TGF, transforming growth factor; TNF, tumor necrosis factor; and TSH, thyroid stimulating hormone.
*For the continuous variables, Tukey adjustment was used for pairwise comparisons (see Table II in the Data Supplement for adjusted comparisons between groups 1 and 2 for selected biomarkers).
the cardiac structure and function of patients in group 3 can be found in Table I in the Data Supplement.
Characteristics of Anemia
Despite having at least moderate CKD, only 55% of patients in group 3 had anemia, and hemoglobin was lower in patients in group 1 than in those in group 3. Erythropoietin values were significantly higher in group 1 (20.4 [13.5, 31.2] pg/mL) when compared with those in groups 2 (12.7 [8.5, 18.5] pg/mL) and 3 (13.0 [9.5, 16.6] pg/mL). Vitamin B12 and folic acid were normal in the vast majority of patients and did not differ between groups (data not shown), as expected based on exclusion criteria. On the basis of STfR/log (ferritin) ratio and ferritin levels, 15 14.9% of patients in group 1 were found to have iron deficiency anemia when compared with only 3.7% of patients in group 3 (data not shown). Thyroid stimulating hormone levels above the central laboratory reference range of 4.2 mU/L were found in 19.1% of patients in group 1, 9.4% of patients in group 2, and 12.2% of patients in group 3 (P values between groups >0.1; Table 2 ).
Renal Function
Patients in group 1 had more advanced CKD than patients in group 2 (mean eGFR, 47.1±17.6 versus 70.1±23.1 mL/ min per 1.73 m 2 , P<0.0001), but their eGFR was not statistically different than that of patients in the CKD group 3 (40.9±12.3 mL/min per 1.73 m 2 ; P=0.12 between groups 1 and 3). Both cystatin C and neutrophil gelatinase-associated lipocalin were significantly higher in group 1 than in group 2 (Table 2) ; however, these markers of renal dysfunction, as eGFR, did not differ between groups 1 and 3 (P=1.0 and 0.92, respectively). Correlation coefficients between hemoglobin and cystatin C were −0.56 (P<0.0001) in groups 1 and 2 combined and −0.33 (P=0.02) in group 3. All other markers of renal function (eGFR, blood urea nitrogen/creatinine ratio, and neutrophil gelatinase-associated lipocalin) had weaker correlations with hemoglobin, with eGFR (correlation coefficient, 0.49; P<0.0001) performing best after cystatin C (data not shown).
Inflammation
The IL-6 (P=0.0009) and IL-10 levels (P=0.05) were higher in group 1 when compared with those in group 2. IL-1β was the only inflammatory marker that differed significantly between groups 1 and 3 (higher in group 1). An inflammatory pattern was seen as frequently in group 1 as in group 3 on protein electrophoresis. A small proportion of patients was newly found to have monoclonal gammopathy in all 3 groups (3%-6%, data not shown).
LV Remodeling by Echocardiography and Serum Biomarkers
Patients in group 1 had greater LV remodeling when compared with patients in the other 2 groups. They had a higher LV mass index, more mitral regurgitation, and a larger left atrial end-systolic volume index (Table I in the Data Supplement) . Also, right ventricular systolic pressure was highest in group 1 and lowest in group 3. LVEF ( Serum biomarkers related to collagen turnover and LV remodeling (Table 2) did not significantly differ between groups 1 and 3. However, procollagen type III N-terminal peptide, MMP-2, and TIMP-1 were all significantly higher in group 1 when compared with those in group 2.
Biomarkers Independently Related to Anemia in HF
When groups 1 and 2 were compared after adjustment for several cofactors or comorbid conditions (Table II in the Data Supplement), the markers of renal function (except neutrophil gelatinase-associated lipocalin), IL-10, and the MMP-9/ TIMP-1 ratio remained statistically different between patients with anemia and nonanemia.
We also examined the predictors of hemoglobin as a continuous variable in patients with HFrEF, including the same variables as in Table II in the Data Supplement in this analysis but with eGFR representing renal function. We also added IL-10 and the MMP-9/TIMP-1 ratio to this analysis, as per the above results. For groups 1 and 2 combined (HFrEF), lower eGFR (P<0.0001), female sex (P=0.007), and higher IL-10 levels (P=0.04) were independent predictors of lower hemoglobin.
Conducting the same multivariable analysis as above in group 3, we found that only female sex (P=0.01) and lower MMP-9/TIMP-1 ratio (P=0.001) were independent predictors of lower hemoglobin.
Discussion
The main objective of this study was to improve our understanding of how patients with HFrEF and anemia differ from subjects with the same condition but without anemia, and from subjects with CKD and preserved EF. Our specific aims were to clarify the role of CKD in anemia associated with HF further, and to understand how markers of LV remodeling and inflammation differ between patients with anemia and nonanemia with HFrEF. We think that these comparisons can help shed light on how anemia confers a worse prognosis in HF. In agreement with previous studies, we found that patients with anemia and HFrEF had more symptoms and higher levels of markers of advanced HF, but we also demonstrated that they had more adverse LV remodeling on echocardiography, despite having similar LVEF (groups 1 and 2). Patients with anemia also had higher erythropoietin values, worse renal function, and exhibited more inflammation and activation of biomarkers associated with LV remodeling. High erythropoietin levels have previously been demonstrated and may suggest an adequate response to anemia in patients with HFrEF, where erythropoietin resistance is most likely involved. 16 Although the use of oral anticoagulants was higher in patients with anemia and HFrEF, this does not necessarily imply a causal relationship, particularly as iron deficiency anemia was infrequent in our cohort of patients.
The association between anemia and adverse LV remodeling is particularly interesting, especially in light of our findings on inflammatory markers, as we will detail below.
Using multivariable analyses, we found that female sex, eGFR, and higher IL-10 levels were the strongest predictors of lower hemoglobin in patients with HFrEF. Patients with CKD and preserved EF differed in many ways from patients with anemia and HFrEF. The 10% rate of hospitalization for HF within 1 year in patients with CKD may reflect the presence of HF with preserved EF in this group. There is a recognized association between those 2 conditions, related to the reduced ability of patients with CKD to control (and adapt to) volume overload.
Renal dysfunction is a major contributor to the pathophysiology of anemia in HF, 1, 2, 4, 17 and it was also the strongest predictor of lower hemoglobin in our study. Cystatin C showed a stronger correlation with hemoglobin than did eGFR. Despite very similar levels of renal dysfunction, patients in groups 1 and 3 largely differed in their biomarkers profiles, demonstrating the many processes other than those related to CKD are involved in the development of anemia in the presence of LV systolic dysfunction. These mechanisms, which are directly involved in the pathophysiology of systolic HF, seem much more active in patients with anemia and HFrEF than in those without anemia. We indeed observed that levels of markers of inflammation, LV remodeling, myocardial stretch (NT-proBNP), and myocyte death (troponin T) are higher in patients with HFrEF and anemia than in those without anemia.
About inflammatory pathways, IL-6 was significantly higher in patients with HFrEF and anemia than in the other 2 groups, intermediate in patients with CKD, and the lowest in patients with HFrEF without anemia. The IL-6 levels reported here were lower than those obtained in the Coordinating Study Evaluating Outcomes of Advising and Counseling in HF (median, 12.0 [7.1-25.5] pg/mL) 18 ; which included patients hospitalized for HF. This difference can be explained by the fact that patients in our study had chronic stable HF rather than acute HF. In Coordinating Study Evaluating Outcomes of Advising and Counseling in HF, 18 high-sensitivity-C-reactive protein also differed between patients with anemia and without anemia with a median of 3.4 (1.3-6.6) mg/L in patients with acute HF and anemia. We observed lower levels of high-sensitivity-C-reactive protein in patients with chronic HFrEF and anemia (median value of 2.6 (1.1-5.2) mg/L), which did not differ from patients in either groups 2 or 3. The IL-6 and high-sensitivity-C-reactive protein levels we observed were similar to those recently reported in stable chronic HF. 19 In patients with HFrEF, levels of TNF-α, transforming growth factor, and the proportion of patients with detectable levels of IL-1β did not significantly differ, regardless of the presence of anemia. However, variable differences in these biomarkers existed between patients with HFrEF and those of group 3. IL-6, involved in a major apoptosis signaling pathway that is upregulated in chronic HF, 20 differed across groups: with group 1 having the highest values and group 2 having intermediate values. Levels of IL-10, which suppresses the production of TNF-α and other proinflammatory cytokines and counteracts many of the adverse effects of TNF-α on cardiac function, 21 were higher in group 1 when compared with those in group 2 but were comparable between groups 1 and 3. Once known independent predictors of worse prognosis in HF were accounted for in patients with HFrEF, IL-10 was the only inflammatory marker that remained different between patients with anemia and nonanemia (adjusted P=0.035). Similar results were observed in patients with chronic obstructive pulmonary disease, 22 where higher levels were documented in anemic patients with chronic obstructive pulmonary disease (25.6 [1.9-95.2] pg/mL) than those observed here in patients with HFrEF and anemia. Interestingly, IL-10 was recently proposed as a potential therapeutic approach to limit the progression of pressure overload-induced adverse cardiac remodeling. 23 However, volume overload seems to be a concern in patients with HF and anemia.
Our results indicate a active LV remodeling process in patients with anemia and HFrEF, as shown by increased procollagen type III N-terminal peptide, MMP-2, and TIMP-1 levels in group 1 when compared with those in group 2. The fact that patients in group 1 more frequently received mineralocorticoid receptor antagonists could have favorably modified the levels of remodeling biomarkers 24 but the latter remained higher in this anemic group. The MMP-9/TIMP-1 ratio was the only marker of LV remodeling that remained significantly different between patients with and without anemia with HFrEF, after adjustment for well-established markers of prognosis, suggesting that this relationship is complex (Table II in the Data Supplement). The MMP-9/TIMP-1 ratio was lower in group 1, reflecting higher levels of inhibition of the degradation process (higher TIMP-1 levels; Table 2 ) in patients with anemia. This ratio has also been correlated to severity of disease and mortality in sepsis. 25 In their study, Lorente et al 25 demonstrated that nonsurviving sepsis patients had a lower MMP-9/TIMP-1 ratio (P=0.003), and higher levels of IL-10 (P<0.001), than did survivors. The latter biomarker profiles of nonsurviving sepsis patients are thus similar to those of anemic HFrEF patients. In terms of interactions between pathophysiological pathways, the anti-inflammatory cytokine IL-10 has been shown to induce TIMP-1 and reduce MMP-9 expression in endothelium/monocyte cocultures and is proposed as an important modulator of monocyte-endothelial cell interactions. 26 Cytokine-induced monocyte-endothelial interaction and vascular inflammation play a critical role in atherogenesis, another potential link between prognosis and anemia in HF.
The echocardiographic markers of remodeling, LV mass, and left atrial volume indices were increased in patients with anemia when compared with those with nonanemia and HFrEF (Table I in the Data Supplement). These parameters have consistently been associated with cardiovascular outcomes in HF and were markedly increased in our patients with anemia and HFrEF. In patients with chronic anemia but without HF, increased cardiac output, as a result of anemia, may lead to progressive cardiac enlargement, LV hypertrophy, and left atrial enlargement, as was found in our study. The higher values of NT-proBNP (reflecting myocardial stretch) in group 1 also favor the above remodeling hypotheses.
Troponin T was elevated in patients with HFrEF, suggesting an ongoing adverse cellular necrotic process. However, the proportion of patients with elevated troponin T levels did not remain statistically different between patients with and without anemia once other markers of prognosis were considered, suggesting that this elevation was multifactorial in nature.
In multivariable analysis, a recent hospitalization was identified as an independent predictor of lower hemoglobin, which, in addition to reflecting the severity and activity of the disease, may also indirectly point to congestion as a major contributor to anemia. In a study involving 196 patients with advanced HF, Androne et al 6 directly assessed hemodilution, which was present in 46% of the subset of 37 patients with ambulatory anemia. In our study, 43.8% of patients with anemia and HFrEF had jugular vein distension, and 45.8% had peripheral edema. The prevalence of these markers of congestion was much lower in patients with HFrEF without anemia (24.1% and 18.5%). More signs of congestion observed in patients with anemia (increased jugular venous pressure, peripheral edema, higher bilirubin levels, and lower platelet counts) suggest that hemodilution and right HF were significant contributors to anemia. To compensate for hemodilution, jugular vein distension was included in our adjusted analysis of other potential drivers of anemia (Table II in the Data Supplement). These findings and those of previous mechanistic studies on hemodilution should prompt control of volume overload before considering other treatments of anemia in HF. Targeting inflammation (possibly through IL-10), myocardial remodeling, and volume overload should be considered in the treatment of patients with anemia and HF.
Limitations
We have used a cross-sectional study design, with a relatively small number of patients per group. Nevertheless, our sample size is similar to that of other studies on mechanisms of anemia in HF and was sufficient to observe significant, clinically meaningful differences in multiple biomarkers between groups. Sample size determination was based on TNF-α levels using older enzymatic assays in previous cohorts, leading to lower observed TNF-α concentrations. However, the observed levels of key inflammatory markers compared well with those reported in current literature. 19 The results of our multivariable analysis need to be interpreted keeping the sample size in mind and will need to be replicated in future studies.
Conclusions
Anemia is strongly associated with the level of renal dysfunction in HFrEF, but more importantly, it is indicative of a complex interplay between pathophysiological mechanisms, portraying a more advanced and active heart disease. These mechanisms include increased myocardial remodeling, inflammation, and volume overload, hallmarks of patients with anemia and HF.
